User menu

Corticosteroids in the management of acute multiple sclerosis exacerbations.

Bibliographic reference Smets, I ; Van Deun, L ; Bohyn, C ; Van Pesch, Vincent ; Vanopdenbosch, L ; et. al. Corticosteroids in the management of acute multiple sclerosis exacerbations.. In: Acta Neurologica Belgica, (2017)
Permanent URL http://hdl.handle.net/2078.1/185958
  1. Compston Alastair, Coles Alasdair, Multiple sclerosis, 10.1016/s0140-6736(08)61620-7
  2. Confavreux Christian, Vukusic Sandra, Natural history of multiple sclerosis: a unifying concept, 10.1093/brain/awl007
  3. Scalfari Antonio, Neuhaus Anneke, Degenhardt Alexandra, Rice George P., Muraro Paolo A., Daumer Martin, Ebers George C., The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability, 10.1093/brain/awq118
  4. Frohman Elliot M., Shah Anjali, Eggenberger Eric, Metz Luanne, Zivadinov Robert, Stüve Olaf, Corticosteroids for multiple sclerosis: I. Application for treating exacerbations, 10.1016/j.nurt.2007.07.008
  5. Stahn Cindy, Löwenberg Mark, Hommes Daniel W., Buttgereit Frank, Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists, 10.1016/j.mce.2007.05.019
  6. Sloka J S, Stefanelli M, The mechanism of action of methylprednisolone in the treatment of multiple sclerosis, 10.1191/1352458505ms1190oa
  7. GALON J., Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells, 10.1096/fj.01-0245com
  8. Almawi WY, Beyhum HN, Rahme AA, Rieder MJ (1996) Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 60(5):563–572
  9. Martínez-Cáceres E. M., Barrau M. A., Brieva L., Espejo C., Barberà N., Montalban X., Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects, 10.1046/j.1365-2249.2002.01725.x
  10. Polman Chris H., Reingold Stephen C., Banwell Brenda, Clanet Michel, Cohen Jeffrey A., Filippi Massimo, Fujihara Kazuo, Havrdova Eva, Hutchinson Michael, Kappos Ludwig, Lublin Fred D., Montalban Xavier, O'Connor Paul, Sandberg-Wollheim Magnhild, Thompson Alan J., Waubant Emmanuelle, Weinshenker Brian, Wolinsky Jerry S., Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria, 10.1002/ana.22366
  11. Guthrie Thomas C., Nelson Dewey A., Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential, 10.1016/0022-510x(94)00248-m
  12. D'hooghe MB, Nagels G., Bissay V., De Keyser J., Modifiable factors influencing relapses and disability in multiple sclerosis, 10.1177/1352458510367721
  13. Correale J., Fiol M., Gilmore W., The risk of relapses in multiple sclerosis during systemic infections, 10.1212/01.wnl.0000233834.09743.3b
  14. Mohr D. C, Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis, 10.1136/bmj.38041.724421.55
  15. Citterio Antonietta, La Mantia Loredana, Ciucci Gabriele, Candelise Livia, Brusaferri Fabio, Midgard Rune, Filippini Graziella, Corticosteroids or ACTH for acute exacerbations in multiple sclerosis, 10.1002/14651858.cd001331
  16. Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW (1970) Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo—final report. Neurology 20(5):1–59
  17. Brusaferri Fabio, Candelise Livia, Steriods for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials, 10.1007/s004150070172
  18. Miller Deborah M, Weinstock-Guttman Bianca, Béthoux François, Lee Jar-Chi, Beck Gerald, Block Vicki, Durelli Luca, LaMantia Loredana, Barnes David, Sellebjerg Finn, Rudick Richard A, A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations, 10.1177/135245850000600408
  19. Ramo-Tello Cristina, Tintoré Mar, Rovira Alex, Ramió-Torrenta Luis, Brieva Luis, Saiz Albert, Cano Antonio, Carmona Olga, Hervás Jose V, Grau-López Laia, Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses, 10.1177/1352458515590648
  20. Beck Roy W., Cleary Patricia A., Anderson Malcolm M., Keltner John L., Shults William T., Kaufman David I., Buckley Edward G., Corbett James J., Kupersmith Mark J., Miller Neil R., Savino Peter J., Guy John R., Trobe Jonathan D., McCrary John A., Smith Craig H., Chrousos Georgia A., Thompson H. Stanley, Katz Barrett J., Brodsky Michael C., Goodwin James A., Atwell Constance W., A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis, 10.1056/nejm199202273260901
  21. Beck Roy W., Cleary Patricia A., Trobe Jonathan D., Kaufman David I., Kupersmith Mark J., Paty Donald W., Brown C. Hendricks, The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple Sclerosis, 10.1056/nejm199312093292403
  22. Goodin Douglas S., Perils and Pitfalls in the Interpretation of Clinical Trials: A Reflection on the Recent Experience in Multiple Sclerosis, 10.1159/000069408
  23. Sellebjerg F., Frederiksen J. L., Nielsen P. M., Olesen J., Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS, 10.1212/wnl.51.2.529
  24. Miller Henry, Newell D.J., Ridley Alan, MULTIPLE SCLEROSIS TREATMENT OF ACUTE EXACERBATIONS WITH CORTICOTROPHIN (A.C.T.H.), 10.1016/s0140-6736(61)91030-3
  25. Durelli L., Cocito D., Riccio A., Barile C., Bergamasco B., Baggio G. F., Perla F., Delsedime M., Gusmaroli G., Bergamini L., High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlations, 10.1212/wnl.36.2.238
  26. Milligan N M, Newcombe R, Compston D A, A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects., 10.1136/jnnp.50.5.511
  27. Filipović Saša R, Drulović Jelena, Stojsavljević Nebojša, Lević Zvonimir, The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis, 10.1016/s0022-510x(97)00159-7
  28. La Mantia L., Eoli M., Milanese C., Salmaggi A., Dufour A., Torri V., Double-Blind Trial of Dexamethasone versus Methylprednisolone in Multiple Sclerosis Acute Relapses, 10.1159/000117038
  29. Milanese C., La Mantia L., Salmaggi A., Campi A., Eoli M., Scaioli V., Nespolo A., Corridori F., Double-Blind Randomized Trial of ACTH versus Dexamethasone versus Methylprednisolone in Multiple Sclerosis Bouts, 10.1159/000116368
  30. Tandon R, Verma K, Chawla B, Sharma N, Titiyal J S, Kalaivani M, Vajpayee R B, Intravenous dexamethasone vs methylprednisolone pulse therapy in the treatment of acute endothelial graft rejection, 10.1038/eye.2008.25
  31. Thompson A. J., Kennard C., Swash M., Summers B., Yuill G. M., Shepherd D. I., Roche S., Perkin G. D., Loizou L. A., Ferner R., Hughes R.A.C., Thompson M., Hand J., Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS, 10.1212/wnl.39.7.969
  32. Burton Jodie M, O'Connor Paul W, Hohol Marika, Beyene Joseph, Oral versus intravenous steroids for treatment of relapses in multiple sclerosis, 10.1002/14651858.cd006921.pub3
  33. Le Page Emmanuelle, Veillard David, Laplaud David A, Hamonic Stéphanie, Wardi Rasha, Lebrun Christine, Zagnoli Fabien, Wiertlewski Sandrine, Deburghgraeve Véronique, Coustans Marc, Edan Gilles, Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial, 10.1016/s0140-6736(15)61137-0
  34. Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió i Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalbán X, Martínez-Cáceres E, Costa J, A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS, 10.1177/1352458513508835
  35. Martinelli V., Rocca M. A., Annovazzi P., Pulizzi A., Rodegher M., Boneschi F. M., Scotti R., Falini A., Sormani M. P., Comi G., Filippi M., A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS, 10.1212/wnl.0b013e3181c3fd5b
  36. Morrow S. A., Stoian C. A., Dmitrovic J., Chan S. C., Metz L. M., The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis, 10.1212/01.wnl.0000138572.82125.f5
  37. Grau-López L, Teniente-Serra A, Tintoré M, Rovira A, Ramió-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervás JV, Martínez-Cáceres EM, Ramo-Tello C, Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses, 10.1177/1352458514546786
  38. Comi Giancarlo, Radaelli Marta, Oral corticosteroids for multiple sclerosis relapse, 10.1016/s0140-6736(15)00072-0
  39. Kister Ilya, Corboy John R., Reducing costs while enhancing quality of care in MS: Table, 10.1212/wnl.0000000000003113
  40. Alam S M, Kyriakides T, Lawden M, Newman P K, Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose., 10.1136/jnnp.56.11.1219
  41. Barnes D, Hughes RAC, Morris RW, Wade-Jones O, Brown P, Britton T, Francis DA, Perkin GD, Rudge P, Swash M, Katifi H, Farmer S, Frankel J, Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis, 10.1016/s0140-6736(96)06453-7
  42. Caster Ola, Edwards I. Ralph, Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses, 10.1186/s12883-015-0450-x
  43. Lević Zvonimir, Micić D., Nikolić J., Stojisavljević N., Sokić D., Janković S., Kendereški A., Mavra M., Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test, 10.1007/bf03347855
  44. Visser L H, Beekman R, Tijssen C C, Uitdehaag B MJ, Lee M L, Movig K LL, Lenderink A W, A randomized, double-blind, placebo-controlled pilot study of IV immune globulins in combination with IV methylprednisolone in the treatment of relapses in patients with MS, 10.1191/1352458504ms978sr
  45. Iuliano Gerardo, Napoletano Rosa, Esposito Antonio, Multiple Sclerosis: Relapses and Timing of Remissions, 10.1159/000109260
  46. Confavreux Christian, O'Connor Paul, Comi Giancarlo, Freedman Mark S, Miller Aaron E, Olsson Tomas P, Wolinsky Jerry S, Bagulho Teresa, Delhay Jean-Luc, Dukovic Deborah, Truffinet Philippe, Kappos Ludwig, Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial, 10.1016/s1474-4422(13)70308-9
  47. Fox Robert J., Miller David H., Phillips J. Theodore, Hutchinson Michael, Havrdova Eva, Kita Mariko, Yang Minhua, Raghupathi Kartik, Novas Mark, Sweetser Marianne T., Viglietta Vissia, Dawson Katherine T., Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis, 10.1056/nejmoa1206328
  48. Mikol Daniel D, Barkhof Frederik, Chang Peter, Coyle Patricia K, Jeffery Douglas R, Schwid Steven R, Stubinski Bettina, Uitdehaag Bernard MJ, Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial, 10.1016/s1474-4422(08)70200-x
  49. Cohen Jeffrey A, Coles Alasdair J, Arnold Douglas L, Confavreux Christian, Fox Edward J, Hartung Hans-Peter, Havrdova Eva, Selmaj Krzysztof W, Weiner Howard L, Fisher Elizabeth, Brinar Vesna V, Giovannoni Gavin, Stojanovic Miroslav, Ertik Bella I, Lake Stephen L, Margolin David H, Panzara Michael A, Compston D Alastair S, Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial, 10.1016/s0140-6736(12)61769-3
  50. Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis, 10.1056/nejmoa0802670
  51. Polman Chris H., O'Connor Paul W., Havrdova Eva, Hutchinson Michael, Kappos Ludwig, Miller David H., Phillips J. Theodore, Lublin Fred D., Giovannoni Gavin, Wajgt Andrzej, Toal Martin, Lynn Frances, Panzara Michael A., Sandrock Alfred W., A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis, 10.1056/nejmoa044397
  52. Miller David H, Fazekas Franz, Montalban Xavier, Reingold Stephen C, Trojano Maria, Pregnancy, sex and hormonal factors in multiple sclerosis, 10.1177/1352458513519840
  53. Vukusic Sandra, Marignier Romain, Multiple sclerosis and pregnancy in the 'treatment era', 10.1038/nrneurol.2015.53
  54. Houtchens Maria K., Kolb Channa M., Multiple sclerosis and pregnancy: therapeutic considerations, 10.1007/s00415-012-6653-9
  55. Lyons P R, Newman P K, Saunders M, Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects., 10.1136/jnnp.51.2.285
  56. Carpani de Kaski M, Rentsch R, Levi S, Hodgson H J, Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers., 10.1136/gut.37.5.613
  57. Guslandi M., Tittobello A., Steroid ulcers: a myth revisited., 10.1136/bmj.304.6828.655-a
  58. Poetker David M., Reh Douglas D., A Comprehensive Review of the Adverse Effects of Systemic Corticosteroids, 10.1016/j.otc.2010.04.003
  59. Warrington Thomas P., Bostwick J. Michael, Psychiatric Adverse Effects of Corticosteroids, 10.4065/81.10.1361
  60. McLuckie Lt Alan E., Savage Cdr Rodney W, Atrial Fibrillation Following Pulse Methylprednisolone Therapy in an Adult, 10.1378/chest.104.2.622
  61. Moretti R., Torre P., Antonello R. M., Zorzon M., Cazzato G., Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: a possible prophylactic treatment : Letter to the editor, 10.1046/j.1468-1331.2000.00026.x
  62. Caster Ola, Conforti Anita, Viola Ermelinda, Edwards I. Ralph, Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance, 10.1007/s00228-013-1632-3
  63. Gutkowski Krzysztof, Chwist Alina, Hartleb Marek, Liver Injury Induced by High-Dose Methylprednisolone Therapy: A Case Report and Brief Review of the Literature, 10.5812/kowsar.1735143x.641
  64. Lopez-Serrano MC, Moreno-Ancillo A, Contreras J, Ortega N, Cabanas R, Barranco P, Munoz-Pereira M (1996) Two cases of specific adverse reactions to systemic corticosteroids. J Investig Allergol Clin Immunol 6(5):324–327
  65. Tüzün Şansin, AltWntaş Ayşe, Karacan İlhan, Tangürek Saliha, Saip Sebahattin, Siva Aksel, Bone status in multiple sclerosis: beyond corticosteroids, 10.1191/1352458503ms966oa
  66. Zorzon M., Zivadinov R., Locatelli L., Giuntini D., Toncic M., Bosco A., Nasuelli D., Bratina A., Tommasi M. A., Rudick R. A., Cazzato G., Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis, 10.1111/j.1468-1331.2005.00988.x
  67. Sahraian M. A., Yadegari S., Azarpajouh R., Forughipour M., Avascular necrosis of the femoral head in multiple sclerosis: report of five patients, 10.1007/s10072-011-0914-8
  68. Costedoat-Chalumeau Nathalie, Amoura Zahir, Aymard Guy, Sevin Odile, Wechsler Bertrand, Cacoub Patrice, Du Le Thi Huong, Diquet Bertrand, Ankri Annick, Piette Jean-Charles, Potentiation of Vitamin K Antagonists by High-Dose Intravenous Methylprednisolone, 10.7326/0003-4819-132-8-200004180-00005
  69. Hazlewood Kathleen A, Fugate Susan E, Harrison Donald L, Effect of Oral Corticosteroids on Chronic Warfarin Therapy, 10.1345/aph.1h418
  70. Varis T., Kivistö K. T., Neuvonen P. J., The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone, 10.1007/s002280050720
  71. Weinshenker Brian G., O'Brien Peter C., Petterson Tanya M., Noseworthy John H., Lucchinetti Claudia F., Dodick David W., Pineda Alvaro A., Stevens Lorna N., Rodriguez Moses, A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease, 10.1002/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q
  72. Klingel Reinhard, Heibges Andreas, Fassbender Cordula, Plasma exchange and immunoadsorption for autoimmune neurologic diseases – current guidelines and future perspectives, 10.1016/s1567-5688(09)71827-6